Hedge Funds Aren't Crazy About Brainstorm Cell Therapeutics Inc. (BCLI) AnymoreInsider Monkey • 11/27/20
BrainStorm to present NurOwn® Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MNDPRNewsWire • 11/23/20
Brainstorm Cell Therapeutics News: 8 Things for BCLI Stock Investors to Know About the ALS StudyInvestorPlace • 11/17/20
Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing FacilityPRNewsWire • 10/26/20
Brainstorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/15/20
BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate UpdatePRNewsWire • 10/15/20
BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Corporate UpdatePRNewsWire • 10/02/20
BrainStorm Appoints Pharmaceutical Veteran Anthony Waclawski as Executive Vice President, Global Head of Regulatory AffairsGlobeNewsWire • 09/02/20
BrainStorm to Present Data Linking MRI Measures to Functional Improvement in Progressive Multiple Sclerosis (MS)PRNewsWire • 08/25/20
BrainStorm Announces Publication of New Preclinical Data Supporting Proposed NurOwn® Mechanism in ALS, Progressive MS and Alzheimer's DiseasePRNewsWire • 08/19/20
Brainstorm Cell Therapeutics Inc (BCLI) CEO Chaim Lebovits on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/05/20
BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDSGlobeNewsWire • 07/23/20
BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer's Disease ProgramPRNewsWire • 07/08/20
BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALSPRNewsWire • 07/02/20
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for the Treatment of Alzheimer's DiseasePRNewsWire • 06/24/20